Tiziana Life Sciences LtdNASDAQ:TLSANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.8151
- TODAY'S CHANGE (%)-0.0260 (-3.0912%)
- Bid / Lots0.8151/ 38
- Ask / Lots0.8400/ 11
- Open / Previous Close0.8100 / 0.8411
- Day Range
- 52 Week Range
- Volume38,096
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TLSA |
|---|---|---|
| 09:32 ET | 12983 | 0.8275 |
| 09:34 ET | 12848 | 0.8152 |
| 09:36 ET | 1428 | 0.8151 |
Yesterday
Apr 23, 2024
Apr 22, 2024
Apr 19, 2024
Apr 18, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tiziana Life Sciences Ltd | 86.0M | -5.4x | --- |
Sellas Life Sciences Group Inc | 85.5M | -1.1x | --- |
Aileron Therapeutics Inc | 84.9M | -1.5x | --- |
InflaRx NV | 81.8M | -1.6x | --- |
PMV Pharmaceuticals Inc | 88.0M | -1.2x | --- |
Allakos Inc | 88.8M | -0.5x | --- |
Company Information
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
Contact Information
- Headquarters
- 3Rd Floor, 11-12 St. James's SquareLONDON, United Kingdom SW1Y 4LB
- Phone
- 207-495-2379
- Fax
- ---
Executives
- Executive Chairman of the Board
- Gabriele Cerrone
- Chief Executive Officer, Chief Scientific Officer, Executive Director
- Kunwar Shailubhai
- Finance Director
- Keeren Shah
- Senior Director, CMC and Non - Clinical Development
- Jules Jacob
- Chief Development Officer
- William Clementi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $86.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 102.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.32 |
EPS | $-0.15 |
Book Value | $0.19 |
P/E Ratio | -5.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
